Xilio Therapeutics is a biotechnology company that discovers and develops immuno-oncology therapeutics for the treatment of lung cancer. Xilio Therapeutics is headquartered in Waltham, Massachusetts, ...

Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Uterine Cancer. According to GlobalData, Phase II drugs for Uterine Cancer have a 30% phase transition ...

The patient was 27 years old and presented with symptoms of irregular uterine bleeding of 3 months' duration and a palpable mass. Gynecologic examination of the case revealed a normal vulva ...

The majority of women with uterine fibroids are asymptomatic, consequently get less clinical attention and fibroid tumors often remain undiagnosed. [23,24] Symptomatic women typically complain ...

Scientific Director, Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch Scientific Director Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch ...